Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

ng on Day 1 of a 21-day cycle. The primary endpoint of this study is overall survival; the secondary endpoints include progression-free survival, overall response rate, duration of response and quality of life.

Pharmion has completed the Scientific Advice (SA) process with the European Medicines Agency (EMEA) and has reached Special Protocol Assessment (SPA) agreement with the US Food and Drug Administration (FDA) for the amrubicin Phase 3 SCLC study.

Interim findings from a Phase 2, multi-center clinical study of amrubicin in second-line sensitive SCLC patients provided encouraging initial results and informed the design of the pivotal study. These data were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2007. Response data from 24 evaluable patients were analyzed, 15 treated with amrubicin and nine with topotecan. Of the 15 amrubicin-treated patients, 40 percent showed an objective tumor response, including two complete responses and four partial responses. All responses were confirmed. None of the nine topotecan patients showed a response to the drug. The median duration of progression free survival at the interim analysis was 4.1 months for amrubicin patients compared to 2.0 months for topotecan patients. Patients are being followed for overall survival. The major toxicity of amrubicin is myelosuppression, which is managed with standard supportive therapy and dose adjustments.

In addition to the Phase 2 study in second-line sensitive SCLC patients, Pharmion has two additional ongoing Phase 2 studies of amrubicin therapy for small cell lung cancer patients; one as single-agent therapy in patients refractory to first-line therapy; and one as single-agent or combination therapy with cisplatin versus cisplatin plus etoposide in previously untreated extensive stage patients.

"The Phase 2 studies in small cell lung cancer, in both sensitive and refractory patients, have thus far generated data f
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Research and Markets ... Advanced Wound Care and Closure Market (Types, Applications, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. The ... closure market (types, applications, end user and geography) ...
(Date:8/20/2014)... 20, 2014  Decision Resources Group finds ... ablation device market will expand through 2023 ... atrial fibrillation (AF). The increasing acceptance of ... AF will spur adoption of premium-priced products ... advanced loop diagnostic catheters, cryoablation catheters and ...
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
Breaking Medicine Technology:Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... a letter dated January 18, 2012 from The Nasdaq Stock ... from the Company,s Board of Directors effective January 4, 2012, ... Nasdaq,s requirement that its audit committee consists of at least ...
... Ind., Jan. 24, 2012 Elanco, the animal health ... LLY ), today announced that Lilly has signed an ... company specializing in the development and commercialization of innovative ... egg, and meat production. Feed enzymes are naturally occurring ...
Cached Medicine Technology:Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement 2Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp. 2Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp. 3Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp. 4
(Date:8/21/2014)... Only 20 percent of healthcare providers currently meet ... according to a new report . , Over 200 ... request from Smart Data pioneer peer60. Participants reported ... violate privacy laws in many states. , “Reaching the ACA’s ... clinics are failing to do so in part because it ...
(Date:8/21/2014)... Crossing, PA (PRWEB) August 21, 2014 ... Washington Crossing Historic Park in Washington Crossing, Pennsylvania on ... maintain the park. “We have been looking for different ... organizations,” said Matt Kiernan, Partner with Pharmica Consulting. “When ... significant part of U.S. history, we jumped at the ...
(Date:8/21/2014)... Teen substance abuse is long been a major issue ... of young adults falling victim to a drug or alcohol ... the community, the new Troubled Teens Boca Raton helpline was ... overcome something like teenage alcohol abuse . The helpline ... best teen recovery facility to focus on achieving sobriety. ...
(Date:8/21/2014)... 21, 2014 Recently nominated as the Women’s ... the journey to be the man he is today. Growing ... had a positive look on women, respecting them as professionals and ... gratefulness and thanks to a man who he had the pleasure ... Stern. , KC Armstrong’s name will ring a bell to most ...
(Date:8/20/2014)... (PRWEB) August 21, 2014 Most people ... the summer months often get overlooked for a variety ... important for food pantries. Understanding this need, Dr. ... chiropractic & natural health care center, wanted to heighten ... clinic hosted its first annual Thanksgiving in July food ...
Breaking Medicine News(10 mins):Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Pharmica Spends the Day Helping to Preserve Washington Crossing Historic Park 2Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:WRNW1's KC Armstrong Expresses Thanks and Appreciation to Howard Stern 2Health News:AlignLife Springfield Office Donates 565 Canned Goods to Springfield Food Pantry 2
... Cleveland Clinic researchers have identified a cellular pathway that cancer ... an aggressive brain tumor. The research published in the ... that existing medications block this cancer-promoting pathway and delay glioma ... these often fatal brain tumors. Malignant gliomas account for ...
... Dennis Thompson HealthDay Reporter , FRIDAY, July 8 (HealthDay ... with red hair, Rothschild admits her compulsion to get a perfect ... said Rothschild, now 27 and living in Northampton, Mass. "I hated ... and thought I looked slimmer" when tan. As a result, ...
... -- Today at the Neglected Tropical Diseases Meeting of ... the Drugs for Neglected Diseases initiative (DNDi) announced the ... infection drug portfolio to address unmet needs of patients ... assess the potential of the drug flubendazole to treat ...
... News) -- Many American teens maintain their religious identity through ... religious activities declines, a new study finds. This was ... Asian, Latin American and European backgrounds -- according to University ... colleagues. The study of 500 teens in the Los ...
... research and treatment of pediatric leukemia at St. Jude Children,s ... Henry M. Stratton Medal from the American Society of Hematology ... the fight against this blood cancer during the past three ... co-founder of Grune and Stratton, the medical publishing house that ...
... , THURSDAY, July 7 (HealthDay News) -- Gonorrhea ... cephalosporins, the only remaining class of antibiotics available to ... report. Researchers analyzed 10 years, worth of gonorrhea ... samples were collected between January 2000 and June 2010 ...
Cached Medicine News:Health News:Brain tumor discovery could lead to new treatment 2Health News:From Tanning Beds to Melanoma Surgery 2Health News:From Tanning Beds to Melanoma Surgery 3Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 2Health News:DNDi expands activities to neglected patient needs in the field of helminth infections 3Health News:Religious Identity Remains Constant in Teen Years: Study 2Health News:Ching-Hon Pui, M.D., honored by the American Society of Hematology for work in childhood cancer 2Health News:Gonorrhea's Growing Resistance to Antibiotics Concerns CDC 2
... is the first hernia repair material ... operative contamination of the material. This ... preservative agents, silver carbonate and chlorhexidine ... colonization on the patch for up ...
... in 1958, Bard mesh has become the ... compared. Bard mesh was used by Dr. ... "tension-free" hernia repair many years ago. Lichtenstein ... ideal" substance for permanent reinforcement of hernia ...
... PerFix plug technique, recommended for the ... indirect and direct inguinal hernias, provides ... technique, requiring less overall dissection and ... repair technique. The result is increased ...
... is a compact, highly portable, single wavelength ... integrated StarPulse feature enables the treatment of ... leg and face, and pigmented surface lesions, ... used as a continuous wave laser for ...
Medicine Products: